Anti-YIPF1/ DJ167A19.1/ FinGER1 monoclonal antibody

Anti-YIPF1/ DJ167A19.1/ FinGER1 antibody for FACS & in-vivo assay

Target products collectionGo to YIPF1/YIPF1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1952-Ab-1/ GM-Tg-hg-MP1952-Ab-2Anti-Human YIPF1 monoclonal antibodyHuman
GM-Tg-rg-MP1952-Ab-1/ GM-Tg-rg-MP1952-Ab-2Anti-Rat YIPF1 monoclonal antibodyRat
GM-Tg-mg-MP1952-Ab-1/ GM-Tg-mg-MP1952-Ab-2Anti-Mouse YIPF1 monoclonal antibodyMouse
GM-Tg-cynog-MP1952-Ab-1/ GM-Tg-cynog-MP1952-Ab-2Anti-Cynomolgus/ Rhesus macaque YIPF1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1952-Ab-1/ GM-Tg-felg-MP1952-Ab-2Anti-Feline YIPF1 monoclonal antibodyFeline
GM-Tg-cang-MP1952-Ab-1/ GM-Tg-cang-MP1952-Ab-2Anti-Canine YIPF1 monoclonal antibodyCanine
GM-Tg-bovg-MP1952-Ab-1/ GM-Tg-bovg-MP1952-Ab-2Anti-Bovine YIPF1 monoclonal antibodyBovine
GM-Tg-equg-MP1952-Ab-1/ GM-Tg-equg-MP1952-Ab-2Anti-Equine YIPF1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1952-Ab-1/ GM-Tg-hg-MP1952-Ab-2; GM-Tg-rg-MP1952-Ab-1/ GM-Tg-rg-MP1952-Ab-2;
GM-Tg-mg-MP1952-Ab-1/ GM-Tg-mg-MP1952-Ab-2; GM-Tg-cynog-MP1952-Ab-1/ GM-Tg-cynog-MP1952-Ab-2;
GM-Tg-felg-MP1952-Ab-1/ GM-Tg-felg-MP1952-Ab-2; GM-Tg-cang-MP1952-Ab-1/ GM-Tg-cang-MP1952-Ab-2;
GM-Tg-bovg-MP1952-Ab-1/ GM-Tg-bovg-MP1952-Ab-2; GM-Tg-equg-MP1952-Ab-1/ GM-Tg-equg-MP1952-Ab-2
Products NameAnti-YIPF1 monoclonal antibody
Formatmab
Target NameYIPF1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-YIPF1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species YIPF1/ DJ167A19.1/ FinGER1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1952
    Target NameYIPF1
    Gene ID54432,230584,298312,714632,489581,101095115,511748,100050435
    Gene Symbol and SynonymsC030002N13Rik,DJ167A19.1,FinGER1,YIPF1
    Uniprot AccessionQ9Y548,Q6P6G5
    Uniprot Entry NameYIPF1_HUMAN,YIPF1_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000058799
    Target ClassificationN/A

    The target: YIPF1, gene name: YIPF1, also named as DJ167A19.1, FinGER1. Predicted to enable small GTPase binding activity. Predicted to be involved in vesicle-mediated transport. Located in several cellular components, including Golgi apparatus subcompartment; nucleoplasm; and transport vesicle. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.